E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute Respiratory Distress Syndrome |
|
E.1.1.1 | Medical condition in easily understood language |
In patients mechanically ventilated in ICU, for reasons that are unclear, their lungs fail and fill with water making breathing difficult. This is termed Acute Respiratory Distress Syndrome (ARDS) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal research question is to determine whether in adult patients with moderate to severe ARDS, human umbilical cord derived CD362 enriched MSCs, (REALIST ORBCEL-C cells) are safe and improve important surrogate clinical outcomes.
The primary objective is to assess the safety of a single intravenous infusion of REALIST ORBCEL-C cells in patients with ARDS. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to determine the effect of a single intravenous infusion of REALIST ORBCEL-C cells on:
1. Physiological indices of respiratory dysfunction reflecting severity of ARDS, as measured by oxygenation index (OI), respiratory compliance, and P/F ratio. 2. Sequential organ failure assessment (SOFA) score. 3. Alveolar and systemic markers of inflammatory responses. 4. Alveolar and systemic markers of cell specific injury.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Moderate to severe ARDS as defined by the Berlin definition a)Onset within 1 week of identified insult b)Within the same 24-hour time period i. Hypoxic respiratory failure (PaO2/ FiO2 ratio less than or equal to 27kPa on PEEP more than or equal to 5cmH2O) ii.Bilateral infiltrates on chest x-ray consistent with pulmonary oedema not explained by another pulmonary pathology iii.Respiratory failure not fully explained by cardiac failure or fluid overload 2. Patient is receiving invasive mechanical ventilation |
|
E.4 | Principal exclusion criteria |
1. More than 48 hours from the onset of ARDS 2. Age <16 years 3. Patient is known to be pregnant 4. Participation in a clinical trial of an investigational medicinal product within 30 days 5. Major trauma in the prior 5 days 6. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last year 7. WHO Class III or IV pulmonary hypertension 8. Venous thromboembolism currently receiving anti-coagulation or within the last 3 months. 9. Currently receiving extracorporeal life support (ECLS) 10. Severe chronic liver disease with Child-Pugh score >12 11. DNAR (Do Not Attempt Resuscitation) order in place 12. Treatment withdrawal imminent within 24 hours 13. Consent declined 14. Prisoners 15. Non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available 16. Previously enrolled in the REALIST trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary safety outcome: The safety and tolerability of MSCs as defined by the incidence of serious adverse events (SAEs)
Primary efficacy outcome: Oxygenation index (OI) at day 7 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
We have chosen day 7 as we expect this time interval will minimise the competing effects of death and extubation while allowing a sufficient time interval for a biological effect to occur. |
|
E.5.2 | Secondary end point(s) |
1) Oxygenation Index (OI) at days 4 and 14 2) Respiratory compliance and P/F ratio at days 4,7 and 14 3) Sequential Organ Failure Assessment (SOFA) score at days 4,7 and 14 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Phase 1: Dose escalation, Phase 2:Randomised, double-blind, controlled |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when all phase 1 and phase 2 patients have completed 2 year follow up and database lock occurs. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |